Vnitr Lek 1995, 41(11):759-763

[Personal experience with replacement therapy with intravenous gamma globulin].

J Litzman, J Lokaj, D Stikarovská, J Mayer, V Thon, M M Eibl

Ustav klinické imunologie LF Masarykovy univerzity, FN u sv. Anny, Brno.

Replacement therapy with intravenous immunoglobulin (IVIG) is currently the therapy of choice in patients with antibody-formation deficiency. Our 30-month experience with IVIG treatment in 8 patients with common variable immunodeficiency and in 4 patients with x-linked agammaglobulinemia previously treated by intramuscular immunoglobulin or low-dose IVIG is presented. Long-term dosage was 400 mg/kg once in 3--4 weeks. Ten patients reported an improvement of their health state, especially the signs of their chronic bronchitis improved. Compared to 2 cases of pneumonia which occurred within 30 months before IVIG therapy had started, no case of pneumonia occurred during IVIG treatment. Infusion rate of 4 mg/kg/min was safe enough in 11 of our patients. Serum trough IgG level is the most important for laboratory monitoring of the patients under IVIG therapy.

Keywords: Adult; Agammaglobulinemia, immunology, ; Common Variable Immunodeficiency, immunology, ; Female; Humans; Immunoglobulins, Intravenous, adverse effects, ; Male; Middle Aged

Published: November 1, 1995  Show citation